MRNA Oct 2022 135.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:28AM EDT. Market open.
Loading interactive chart…
- Editor's pickYahoo Finance Video
Stocks gaining in early trading: Nvidia, AMD, Tesla, Moderna, Gilead
Yahoo Finance Live’s Brad Smith breaks down how stocks are moving in early trading.
- Motley Fool
Is Moderna Stock a Buy Now After the U.K.'s Omicron Vaccine Approval?
Shares of COVID-19 vaccine pioneer Moderna (NASDAQ: MRNA) moved higher on Monday morning, rising more than 3% as the company announced more good news with its virus-fighting efforts. Specifically, Moderna said that it has received approval for use in the U.K. for what the company is calling its "next-generation COVID-19 vaccine." The body oversees immunization approvals in the U.K., and this is the first time that it or any other regulatory agency has approved a bivalent vaccine designed to address the omicron variant.
- Financial Times
UK becomes first country to approve Omicron-specific Covid booster
Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators
© 2022 Yahoo. All rights reserved.
